Megace and Imatinib mesylate drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among 2 people who take Megace and Imatinib mesylate. Common interactions include abdominal pain upper among males.
The phase IV clinical study analyzes what interactions people who take Megace and Imatinib mesylate have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
2 people who take Megace and Imatinib mesylate together, and have interactions are studied.
What is Megace?
Megace has active ingredients of megestrol acetate. It is used in weight loss. Currently, eHealthMe is studying from 9,964 Megace users.
What is Imatinib mesylate?
Imatinib mesylate has active ingredients of imatinib mesylate. It is used in chronic myelogenous leukemia (cml). Currently, eHealthMe is studying from 3,845 Imatinib mesylate users.
Number of Megace and Imatinib mesylate reports submitted per year:
Common Megace and Imatinib Mesylate drug interactions by gender *:
female:
n/a
male:
- Abdominal pain upper
- Anaemia
- Chest discomfort
- Chest pain
- Chronic myeloid leukaemia
- Constipation
- Cough
- Deep vein thrombosis
- Dehydration
- Dyspepsia
Common Megace and Imatinib Mesylate drug interactions by age *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Abdominal pain upper
- Anaemia
- Chest discomfort
- Chest pain
- Chronic myeloid leukaemia
- Constipation
- Cough
- Deep vein thrombosis
- Dehydration
- Dyspepsia
* Approximation only. Some reports may have incomplete information.
Do you take Megace and Imatinib mesylate?
Personalize this study to your gender and ageHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
Related studies
Drug side effects by duration, gender and age:
- Megace side effects (9,964 reports)
- Imatinib mesylate side effects (3,845 reports)
Common Megace drug interactions:
- Megace and Aspirin: 1,386 reports
- Megace and Zofran: 1,212 reports
- Megace and Lasix: 1,071 reports
- Megace and Prednisone: 974 reports
- Megace and Zometa: 883 reports
- Megace and Protonix: 864 reports
- Megace and Morphine: 806 reports
- Megace and Decadron: 756 reports
- Megace and Coumadin: 704 reports
- Megace and Prilosec: 670 reports
Browse interactions between Megace and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zCommon Imatinib mesylate drug interactions:
- Imatinib mesylate and Methotrexate: 168 reports
- Imatinib mesylate and Dasatinib: 154 reports
- Imatinib mesylate and Prednisone: 147 reports
- Imatinib mesylate and Aspirin: 138 reports
- Imatinib mesylate and Cytarabine: 127 reports
- Imatinib mesylate and Hydroxyurea: 126 reports
- Imatinib mesylate and Cyclophosphamide: 117 reports
- Imatinib mesylate and Allopurinol: 102 reports
Browse interactions between Imatinib mesylate and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on megestrol acetate and imatinib mesylate (the active ingredients of Megace and Imatinib mesylate, respectively), and Megace and Imatinib mesylate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Megace and Imatinib mesylate.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Tysabri and Gastric Infection - 8 seconds ago
- Tretinoin and Ventricular Tachycardia - 46 seconds ago
- Tolinase and Heparin drug interaction - 47 seconds ago
- Jantoven and Triamcinolone drug interaction - 51 seconds ago
- Moviprep and Eszopiclone drug interaction - 51 seconds ago
- Amlodipine and Wixela Inhub drug interaction - a minute ago
- Imodium and Neurological Symptom - a minute ago
- Metoprolol Tartrate and Nuedexta drug interaction - a minute ago
- Zetia and Besremi drug interaction - a minute ago
- Aceon and Isosorbide Mononitrate drug interaction - a minute ago